What is Krystal Biotech?
Krystal Biotech is a genetic medicines company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- Genetic medicines
- Headquarters
- Pittsburgh, PA
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; Nasdaq: KRYS
What is Krystal Biotech?
Krystal Biotech is a genetic medicines company headquartered in Pittsburgh, PA.
Krystal Biotech operates in genetic medicines and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around VYJUVEK, Redosable gene therapy, Dermatology pipeline, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, Krystal Biotech is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; Nasdaq: KRYS, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does Krystal Biotech offer?
Krystal Biotech's profile centers on VYJUVEK, Redosable gene therapy, Dermatology pipeline, Respiratory pipeline.
- VYJUVEK· Genetic medicines
- Redosable gene therapy· Genetic medicines
- Dermatology pipeline· Genetic medicines
- Respiratory pipeline· Genetic medicines
- Aesthetics· Genetic medicines
- HSV-1 vector platform· Genetic medicines
How does Krystal Biotech make money?
Krystal Biotech makes money through commercial activity tied to genetic medicines.
Krystal Biotech monetizes through the commercial model common to genetic medicines: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads Krystal Biotech?
Krystal Biotech's named executives should be verified on the official leadership or investor-relations page before outreach.
- Krystal Biotech executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Krystal Biotech finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Krystal Biotech technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Krystal Biotech's leadership?
Krystal Biotech should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.krystalbio.com- Krystal Biotech investor relationsInvestor relations / corporate contactcontact via https://www.krystalbio.com
- Krystal Biotech media relationsMedia or communications contact routecontact via https://www.krystalbio.com
How is Krystal Biotech funded?
Krystal Biotech's current status is Public company; Nasdaq: KRYS.
Krystal Biotech's current capital profile is best understood through its current status: Public company; Nasdaq: KRYS. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did Krystal Biotech get here?
Krystal Biotech's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingKrystal Biotech is foundedThe company begins building in genetic medicines.
- Scale-upCommercial footprint expandsKrystal Biotech broadens its product, customer, or geographic reach.
- Capital marketsPublic company; Nasdaq: KRYSOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are Krystal Biotech's competitors?
Krystal Biotech competes with larger platform incumbents and focused specialists in genetic medicines.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
Krystal Biotech — frequently asked questions
